Evidence map›Paper›PMID 42064444›Full record

ReviewFrontiers in chemistry2026

Metal-organic frameworks-mediated reactive oxygen species modulation in the tumor microenvironment of digestive system malignancies: latest advances.

Wei Liu, Chengxin Liu, Meng Wu, Siwen Liu

Abstract readReview
In one paragraph

Review in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wei LiuDepartment of Radiology, The Second Hospital of Jilin University, Changchun, China.
Chengxin LiuDepartment of Radiology, The Second Hospital of Jilin University, Changchun, China.
Meng WuDepartment of Radiology, The Second Hospital of Jilin University, Changchun, China.
Siwen LiuDepartment of Radiology, The Second Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Digestive system malignancies, such as gastric cancer (GC), colorectal cancer (CRC), and hepatocellular carcinoma (HCC), have become a major global challenge in cancer therapy. These tumors are characterized by high morbidity, strong metastatic potential, and significant chemoresistance, thus posing a severe threat to human digestive health. One of the primary mechanisms underlying the malignant progression of tumors and the development of drug-resistant phenotypes is the imbalance of redox homeostasis in the tumor microenvironment (TME). Its dysregulation is strongly associated with the increased proliferation and invasive potential of tumor cells. As key regulatory molecules in the redox network of the TME, reactive oxygen species (ROS) render precise modulation of their levels a promising strategy for cancer therapy. This approach can not only effectively induce programmed cell death in tumor cells but also reverse the immunosuppressive state of the TME, thus offering novel therapeutic targets for anti-tumor treatment. Metal-organic frameworks (MOFs) are closely associated with metal-based nanomaterials, acting as their excellent precursors and enabling precise modulation of their structures and properties through hybridization. The demand for the precise regulation of ROS in the TME of digestive system malignancies is perfectly met by MOFs, which have emerged as a highly promising nanoplatform for this research field. MOFs have unique advantages such as precisely designable architectures, abundant metallic catalytic active sites, TME-responsive degradation, and high drug loading capacity. This review elucidates the mechanisms underlying MOF-mediated ROS modulation in the TME and highlights its applications in various digestive system malignancies.

Indexed as

digestive systemmalignanciesMOFsnanomaterialsROStherapyTME

Identifiers

PMID42064444
PMCPMC13125144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.